People
Wang, who has played a key role in the development of more than 25 innovative medicines at Eli Lilly and GlaxoSmithKline, made him the ideal fit for the company’s next chapter.
The tiny heart organoids, dubbed “cardioids,” even begun beating similarly as real miniature hearts, making them the most realistic heart organoids developed to date.
Maria Fardis, who has been with the company since 2016, stepped down as CEO following FDA’s delay on its Biologics License Application.
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
Forbes highlights its “30 Under 30" list who are beginning to make their mark in the biopharma and healthcare industries.
Shares of Voyager Therapeutics fell in aftermarket trading after its CEO and CMO announced plans to depart the company following clinical setbacks with a Parkinson’s disease program.
Merck Chief Executive Officer Kenneth Frazier has been named CEO of the Year by Chief Executive magazine for his longtime leadership at the pharmaceutical giant.
A new study from Johns Hopkins University Bloomberg School of Public Health suggests the development of dementia is associated with abnormal levels of plasma proteins, and these proteins may be predictive of dementia up to five years before a patient receives a diagnosis.
New pandemic guidelines from the CDC nearly eliminates mask-wearing requirement for fully vaccinated people.
Proxalutamide, a selective high-affinity silent antagonist of the androgen receptor, is being developed by Chinese biotech, Kintor Pharmaceutical Limited (9939.HK).
PRESS RELEASES